US 12,145,959 B2
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
Bronislava Gedulin, Del Mar, CA (US); Michael Grey, Rancho Santa Fe, CA (US); and Niall O'Donnell, Encinitas, CA (US)
Assigned to SHIRE HUMAN GENETIC THERAPIES, INC., Lexington, MA (US)
Filed by SHIRE HUMAN GENETIC THERAPIES, INC., Lexington, MA (US)
Filed on Sep. 23, 2022, as Appl. No. 17/951,326.
Application 17/951,326 is a continuation of application No. 16/696,196, filed on Nov. 26, 2019, abandoned.
Application 16/696,196 is a continuation of application No. 16/031,889, filed on Jul. 10, 2018, abandoned.
Application 16/031,889 is a continuation of application No. 14/354,553, abandoned, previously published as PCT/US2012/062303, filed on Oct. 26, 2012.
Claims priority of provisional application 61/607,487, filed on Mar. 6, 2012.
Claims priority of provisional application 61/553,094, filed on Oct. 28, 2011.
Prior Publication US 2023/0212211 A1, Jul. 6, 2023
Int. Cl. C07H 13/12 (2006.01); A61K 31/155 (2006.01); A61K 31/38 (2006.01); A61K 31/40 (2006.01); A61K 31/4436 (2006.01); A61K 31/4453 (2006.01); A61K 31/454 (2006.01); A61K 31/495 (2006.01); A61K 31/4995 (2006.01); A61K 31/5377 (2006.01); A61K 31/554 (2006.01); A61K 31/7028 (2006.01); A61K 31/7042 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01); A61P 43/00 (2006.01); C07C 257/10 (2006.01); C07C 279/12 (2006.01); C07D 207/04 (2006.01); C07D 211/06 (2006.01); C07D 211/08 (2006.01); C07D 281/10 (2006.01); C07D 285/36 (2006.01); C07D 295/13 (2006.01); C07D 337/08 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 487/08 (2006.01); C07H 15/18 (2006.01); C07H 15/26 (2006.01)
CPC C07H 13/12 (2013.01) [A61K 31/155 (2013.01); A61K 31/38 (2013.01); A61K 31/40 (2013.01); A61K 31/4436 (2013.01); A61K 31/4453 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/4995 (2013.01); A61K 31/5377 (2013.01); A61K 31/554 (2013.01); A61K 31/7028 (2013.01); A61K 31/7042 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01); A61P 43/00 (2018.01); C07C 257/10 (2013.01); C07C 279/12 (2013.01); C07D 207/04 (2013.01); C07D 211/06 (2013.01); C07D 211/08 (2013.01); C07D 281/10 (2013.01); C07D 285/36 (2013.01); C07D 295/13 (2013.01); C07D 337/08 (2013.01); C07D 401/12 (2013.01); C07D 413/12 (2013.01); C07D 487/08 (2013.01); C07H 15/18 (2013.01); C07H 15/26 (2013.01); Y02A 50/30 (2018.01)] 21 Claims
 
1. A method of treating or ameliorating primary biliary cirrhosis (PBC) comprising administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) having a structure

OG Complex Work Unit Chemistry
or a pharmaceutical acceptable salt thereof, wherein the ASTBI decreases pruritis.